Baird downgraded Longboard Pharmaceuticals to Neutral from Outperform with an unchanged price target of $60 after Lundbeck agreed to acquire the company for $60 per share. This is the biggest acquisition in Lundbeck’s history and will be funded with existing cash resources and bank financing, notes the analyst, who views the $2.6B acquisition as taking place at “a reasonable price.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Longboard Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Longboard Pharmaceuticals deal comes earlier than expected, says Truist
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley